Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.98 USD | +1.92% | -4.91% | -12.20% |
02:12pm | Earnings Flash (URGN) UROGEN PHARMA Posts Q1 Revenue $18.8M, vs. Street Est of $21.4M | MT |
05-07 | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.20% | 435M | |
+5.03% | 109B | |
+10.83% | 105B | |
-0.38% | 22.25B | |
-12.31% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-9.07% | 16.85B | |
+4.60% | 13.76B | |
+34.81% | 12.46B |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- UroGen Pharma : Oppenheimer Adjusts UroGen Pharma PT to $34 From $40, Maintains Outperform Rating